UNH: From Healthcare King to $10M Quarterly Profit
Key Takeaways
- UNH's Q4 2025 EPS collapsed to $0.01 on $113 billion revenue, with gross margins falling to 16.3% from 21.7% in Q1.
- Free cash flow declined 37% from $25.7 billion (2023) to $16.1 billion (2025), with further compression likely in 2026.
- Medicare Advantage rate increases of 0.09% versus the expected 4-6% cap the company's revenue recovery potential.
- At $285, the stock trades at 34x the Q2-Q4 earnings run rate — a premium to peers ELV and CI at 10-11x earnings.
- The April 16 earnings report will determine whether Q4 was an anomaly or the new normal for UnitedHealth's profitability.
$10 million. That's what UnitedHealth Group earned in Q4 2025 — on $113 billion of revenue. For context, that's a net margin of 0.009%. A lemonade stand with a good weekend could match it.
UnitedHealth Group (NYSE: UNH) was the largest company in the S&P 500 by revenue. It was the gold standard of managed care — a $600 stock that compounded earnings for two decades straight. Then 2025 happened. The stock sits at $285, down 53% from its 52-week high of $606. The year low hit $235. The medical loss ratio blew out. The CEO resigned under DOJ investigation. And the Trump administration proposed Medicare Advantage rate increases of 0.09% — not the 6% the industry expected.
The question isn't whether UNH is cheap. At 21.6x trailing earnings, it looks reasonable. The question is whether those earnings still exist. Q4 2025 says they don't.
A Profit Collapse in Four Acts
UnitedHealth's 2025 earnings trajectory tells the whole story:
Q1: $6.85 EPS on a 21.7% gross margin. Business as usual.
Q2: $3.74 EPS. Gross margin dropped to 17.9%. Medical costs accelerating.
Q3: $2.59 EPS. Gross margin 18.2%. Operating income fell 53% from Q1.
Q4: $0.01 EPS. Gross margin 16.3%. Operating income collapsed to $380 million — down 96% from Q1's $9.1 billion.
Full-year EPS landed at $13.23 (how to analyze earnings reports), but that number is misleading. Strip out Q1 and the remaining three quarters averaged $2.11 in EPS. Annualize that run rate and you get $8.44 — which puts the stock at 34x forward earnings, not 21x.
The Medical Loss Ratio Problem
Healthcare insurers live and die by one number: the medical care ratio (MCR) — how much of premium revenue goes to paying claims (gross margin vs net margin explained). UnitedHealth's MCR hit 88.9% in 2025, obliterating the historical 82-85% range that made this business a cash machine.
The cost of revenue tells the story. In Q4 alone, UNH spent $94.7 billion against $113.2 billion in revenue. That left $18.5 billion in gross profit — which sounds large until you realize operating expenses consumed $18.1 billion of it, leaving $380 million in operating income.
Post-pandemic utilization is the culprit. Deferred surgeries, diagnostic backlogs, and outpatient procedure volumes have surged. This isn't a one-quarter blip. The trend worsened every quarter through 2025, and there's no evidence it's reversing.
Medicare Advantage: The Regulatory Gut Punch
Medicare Advantage is UnitedHealth's crown jewel — and the government just repriced it.
The Trump administration proposed 2027 MA payment rate increases of just 0.09%. Wall Street had modeled 4-6%. For a business that derives a significant portion of revenue from government programs, this is existential math. Every percentage point of underpayment on MA rates flows directly through to the MCR.
The timing is brutal. UNH was already absorbing a medical cost surge. Now it faces capped revenue growth on its most important business line while costs continue to climb. The company guided for a revenue decline in 2026 — its first annual contraction in over 30 years.
Analyst estimates for 2028 show the uncertainty: EPS projections range from $3.80 to $8.43 per share. That spread — more than 2x between low and high — reflects genuine disagreement about whether UNH can right-size its cost structure or whether the business model itself is impaired.
Cash Flow: The Last Line of Defense
Full-year 2025 operating cash flow came in at $19.7 billion with $16.1 billion in free cash flow. Those are real numbers. But they're deteriorating.
FCF peaked at $25.7 billion in 2023 and has declined 37% in two years. At the current pace, 2026 could see further compression as the MCR headwinds compound.
The balance sheet carries $79.3 billion in debt against $93.4 billion in equity, a 0.83x debt-to-equity ratio. The current ratio is 0.79 — below 1.0, meaning short-term liabilities exceed short-term assets by $24.3 billion. That's manageable for a business generating $20 billion in operating cash flow. It's concerning for a business that just posted a near-zero quarter.
The dividend is the elephant in the room. UNH paid $7.9 billion in dividends in 2025 against $12.8 billion in net income. But if Q4's run rate persists, there's no earnings base to support that payout. Q4's payout ratio was 200%.
The DOJ Overhang and Leadership Vacuum
A Department of Justice investigation into UnitedHealth's business practices adds another layer of risk that's difficult to quantify. Regulatory scrutiny of the managed care industry's vertical integration — UNH owns both the insurer (UnitedHealthcare) and the care provider (Optum) — has intensified.
The company's response? A CEO departure. While officially unrelated, the timing speaks volumes. Institutional investors notice when leadership exits during a crisis rather than through it.
Institutional positioning is mixed. ArrowMark Colorado increased its stake by 22.5%, while Alliancebernstein reduced holdings by 7.5%, selling over 519,000 shares. The smart money is divided, which is rarely a bullish signal.
Valuation: Cheap or Value Trap?
At $285, UNH trades at 21.6x trailing EPS of $13.23 and 3.2x book value. The $259 billion market cap is down from over $550 billion at its peak.
But trailing PE is meaningless when earnings are collapsing. Using the Q2-Q4 run rate of $8.44 annualized EPS, the stock trades at 34x. Using analyst consensus for 2028 ($3.87 to $8.43 EPS), you're paying 34-74x forward earnings three years out.
Enterprise value of $354 billion against 2025 EBITDA makes the EV/EBITDA ratio effectively meaningless — Q4 EBITDA was just $1.4 billion, an annualized rate that prices the stock at 63x EV/EBITDA.
The only metric that still looks reasonable is price-to-cash-flow at ~13x operating cash flow. If FCF stabilizes near $16 billion, there's a floor. But cash flow lags earnings deterioration, and 2026 cash flow hasn't been tested yet.
Compare this to Elevance Health (ELV) at 10x earnings or Cigna (CI) at 11x. UNH commands a premium it no longer deserves.
Conclusion
UnitedHealth Group went from compounding machine to restructuring story in twelve months. The numbers are unambiguous: gross margins collapsed from 21.7% to 16.3%, quarterly EPS fell from $6.85 to $0.01, and free cash flow is down 37% from its 2023 peak. Medicare rate cuts cap the revenue upside. Rising utilization pressures the cost side. And a DOJ investigation clouds the outlook for the industry's most vertically integrated player.
At $285, UNH is not cheap enough to compensate for the risk that Q4's near-zero profit wasn't an anomaly but a preview. Investors looking for managed care exposure should consider ELV or CI at half the valuation multiple. Those who already own UNH should demand evidence that Q1 2026 margins have stabilized before adding to positions. For income investors, understand what dividend yield really tells you before treating UNH as a yield play. The next earnings report on April 16 will be the most consequential in this company's history.
Frequently Asked Questions
Sources & References
www.sec.gov
www.businesswire.com
247wallst.com
Disclaimer: This content is for informational purposes only and does not constitute financial advice. Consult qualified professionals before making investment decisions.